Business Intelligence Awards launched
August 23, 2006Sales and Marketing BHBIA
The first ever awards for business intelligence and market research in the UK pharmaceutical industry have been launched to recognise …
Time to get back to our scientific basics
August 23, 2006Research and Development biotech, drug safety, industry reputation
Recently I was wandering through the local market, and found myself in front of a stall selling therapeutic magnets. I …
New broom Kindler sweeps away Pfizer bureaucracy
August 21, 2006Research and Development, Sales and Marketing
Pfizer's new chief executive Jeffery Kindler has unveiled changes to the company's senior management structure just days into his new …
Pfizer switches agencies in time for Sutent’s UK launch
August 18, 2006Medical Communications Reynolds-Mackenzie, Sutent
Pfizer has enlisted PR agency Reynolds-Mackenzie to support the UK launch and subsequent development of its potential blockbuster kidney cancer …
Head-to-head: Nice and the SMC
August 16, 2006Research and Development, Sales and Marketing NICE, SMC, healthcare
The announcements on NHS budget deficits and the debates surrounding the prescribing of costly drugs, such as in the Herceptin …
NICE gives breast cancer drugs the green light
August 15, 2006Sales and Marketing
Aromatase inhibitors are to become more widely available for post-menopausal women with early breast cancer.As expected, NICE's final appraisal determination …
Vernalis takes diabetes pain drug into phase II
August 15, 2006Research and Development Vernalis
UK biotech company Vernalis has started enrolment into a phase II trial of V3381, a drug designed for patients with …
Huge regional variations in NHS spending revealed
August 11, 2006A new report has revealed large differences in how NHS money is spent across England, with some PCTs spending much …
NHS research could face
August 11, 2006Research and Development
The British Medical Association is questioning the government over a possible 300 million pound drop in funding available for medical …
Empowering patients will cut medication errors, says watchdog
August 11, 2006patients
An NHS watchdog has urged renewed efforts to cut the number of drug errors by improving prescribing and dispensing in …
Generic version of Plavix launched in US
August 10, 2006Sales and Marketing
A generic company has launched a version of blood-thinning blockbuster product Plavix in the US, threatening the $3.3 billion sales …
GSK delivers strong quarterly performance
August 9, 2006Sales and Marketing
GlaxoSmithKline's pharmaceutical sales rose by 10% in this year's second quarter earning the company a total of five billion pounds.Sales …
Lilly’s new products drive up sales
August 8, 2006Sales and Marketing
Accelerated sales of predicted blockbuster depression treatment Cymbalta have helped boost Lilly sales for the second quarter of 2006.The drug …
Identifying and nurturing talent in your salesforce
August 7, 2006Sales and Marketing Schering-Plough, UK, sales, strategy
The aim of every company, pharma or otherwise, is to boost sales and take a greater market share. However, despite …
Takeda selects London for new European business
August 4, 2006Sales and Marketing
Japanese pharmaceutical company Takeda has chosen London as the site of its new four million pound European sales and marketing …
McKinnell makes early exit from Pfizer
August 3, 2006Sales and Marketing Pfizer
Hank McKinnell has stepped down as chief executive of Pfizer earlier than expected following continued criticism of his performance from …
Pfizer’s Sutent receives conditional EMEA approval
August 3, 2006Sales and Marketing
Pfizer's new kidney cancer drug Sutent is rapidly catching up with its recently approved rival, Bayer's Nexavar.Sutent (sunitinib) has been …
Crestor leads AZ European sales growth
August 3, 2006Sales and Marketing
Crestor was AstraZeneca's most rapidly expanding product in terms of European sales in the second quarter of this year. Sales …
Pfizer’s smoking-cessation drug a step closer to European approval
August 3, 2006Sales and Marketing
Pfizer's potential blockbuster smoking cessation drug Champix has been recommended for European approval by a key EMEA committee.The first-in-class treatment …
Study boost for AstraZeneca’s Nexium
August 1, 2006Sales and Marketing
AstraZeneca's blockbuster gastro-oesophageal reflux disease treatment Nexium has come out ahead of Wyeth's Zoton in a new study, which showed …
Latest content
FibroFind appoints Lee Borthwick as CEO
